NEW YORK (GenomeWeb) – BioMérieux said today that its second quarter sales grew 18 percent, as the installed base of its FilmArray platform expanded to nearly 1,900 instruments.
For the three months ended June 30, the Marcy L'Etoile, France-based in vitro diagnostics firm reported revenues of €485.3 million ($526.6 million) compared to €409.9 million in Q2 2014.
This growth included an unspecified positive currency effect. On an organic basis and at constant exchange rates, sales grew 9 percent in Q2. The company noted that for the first half of the year, growth included a 10 percent positive currency effect.
Clinical applications revenues rose 19 percent to €383.7 million from €322.6 million in Q2, while industrial applications sales increased 12 percent to €90.3 million from €80.3 million.
Within clinical applications, the firm's molecular biology sales increased 74 percent year over year to €50.3 million from €29.0 million, and grew by 48 percent on an organic basis. Growth was driven by expansion of the FilmArray installed base and demand for related panels, with the company's easyMAG and Argene lines also reporting sustained sales growth. BioMérieux said that in the first half of the year, sales of its FilmArray platform — which was cleared by the US Food and Drug Administration in February and are manufactured by its BioFire Diagnostics subsidiary — doubled year over year.
Sales for the microbiology segment — which includes the firm's Vitek mass spectrometry platforms and blood culture products — grew 15 percent to €218.2 million from €190.0 million.
Also within clinical applications, immunoassays grew 13 percent to €112.6 million. Of note within industrial applications, BioFire Defense revenues more than doubled to €5.6 million from €2.7 million.
BioMérieux said that, based on the current sales outlook, it is confident it will meet its objective of reporting between 4.5 percent and 6.5 percent organic sales growth in 2015, at constant exchange rates.